HB0036 vs HLX301
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-L1 / TIGIT · full Non-Small Cell Lung Cancer pipeline
HB0036
Developed by Shanghai Huaota Biopharmaceutical Co.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
HLX301
Developed by Shanghai Henlius Biotech
NCT05102214 · Phase 1/2 · status unknown
Patients were assigned to dose-escalation and expansion cohorts without randomization or blinding and without a control arm, so this cannot show whether HLX301 outperforms an alternative treatment. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reported efficacy
Phase 1a: Safety assessments in patients receiving the trial drug (2 years); Phase 1a: The proportion of patients experiencing dose limiting toxicity (DLT) events (From baseline to the end of cycle 2 (28 days)); Phase 1a: The maximum tolerated dose (MTD) of HLX301 (From baseline to the end of cycle 2 (28 days)); Phase 1b: Recommended phase 2 dose (RP2D) (From baseline to 48 weeks after first infusion); Phase 2: Objective response rate (ORR) defined as achieving a complete response or partial response as determined by the investigator according to RECIST v1.1 (2 years); Phase 2: Disease control rate (DCR) defined as achieving the complete response, partial response, or stable disease as determined by the investigator according to RECIST v1.1 (2 years); Phase 2: Duration of response (DOR) defined as the time from the first occurrence of a documented ORR to disease progression, as determined by the investigator according to RECIST v1.1 (2 years): Interim phase 1a dose-escalation data (data cut-off Oct 27, 2023; 9 patients enrolled): 1 patient (11.1%) in the 5.0 mg/kg cohort reported a treatment-related dose-limiting toxicity (grade 3 cytokine release syndrome), and the maximum tolerable dose in this phase 1a was not determined. HLX301 showed an acceptable safety profile with preliminary anti-tumor activity.
Result source: NCT05102214
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | HB0036 | HLX301 |
|---|---|---|
| PFS, median | —Not reported | —Not reported |
| OS, median | —Not reported | —Not reported |
| ORR | —Not reported | —Not reported |
| Duration of response, median | —Not reported | —Not reported |
PFS, median
- HB0036
- —Not reported
- HLX301
- —Not reported
OS, median
- HB0036
- —Not reported
- HLX301
- —Not reported
ORR
- HB0036
- —Not reported
- HLX301
- —Not reported
Duration of response, median
- HB0036
- —Not reported
- HLX301
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
HB0036: no structured comparison results are available for Non-Small Cell Lung Cancer.
HLX301: no structured comparison results are available for Non-Small Cell Lung Cancer.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HB0036's landscape · HLX301's landscape